Exalenz Bioscience Ltd (EXEN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Exalenz Bioscience Ltd (Exalenz) carries out the development and commercialization of advanced medical systems for a range of gastrointestinal (GI) tract and liver disorders. The company harnesses its BreathID technology platform for assessment and monitoring of functional diseases. Its flagship product, BreathID Hp is a urea breath test for diagnosing, monitoring and managing gastric Helicobacter pylori (H. pylori) infection in adults. The BreathID Hp is US Food and Drug Administration (FDA) approved and CE-approved in Europe. The company offers products for detection of gastric adenocarcinoma, peptic ulcer disease and mucosa associated lymphoid tissue lymphoma. It works in collaboration with various clinical and industrial partners in Europe, Asia, the US and Israel. Exalenz is headquartered in Modiin, Israel.